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Abstract
Objective. to describe the clinical characteristics of syndromic neonatal diabetes in a family with a GATA6 mutation.
Clinical case. A girl, current age 10 years 8 months, was born with intrauterine growth retardation: weight 1600 g (-4.3 SDS) at term. After birth, foramen ovale and patent ductus arteriosus (PDA) were diagnosed by echocardiography. Neonatal diabetes was diagnosed at 9 days of age. Exocrine pancreatic insufficiency was clinically diagnosed at about 2 years of age and pancreatic agenesis was revealed later by MRI. Her father underwent surgery during infancy for PDA and developed insulin dependent diabetes at 12 years of age. Ultrasound revealed a thin pancreas with normal length and anatomical structure. He has subclinical exocrine pancreatic insufficiency and no late complications of diabetes. Sequencing of GATA6 identified a heterozygous splicing mutation, 1136-2A>G, in the girl and her father. Testing of the paternal grandparents showed that the mutation was likely to have arisen de novo in the father. 
Conclusion. Identification of a GATA6 mutation explains the cardiac anomalies and diabetes in this family. This case highlights the marked intra-familial variability of both exocrine and endocrine pancreatic phenotypes in patients with GATA6 mutations.

Introduction
Genome sequencing technologies from the last decade have helped to establish the etiology of diabetes mellitus (DM) in a small group of pediatric patients previously considered to have type 1 diabetes. This subgroup differs from type 1 diabetes because the mechanism leading to impaired insulin secretion is non-autoimmune and diabetes is diagnosed in the neonatal period or early infancy. More than 20 genes causing permanent (PNDM) or transient (TNDM) neonatal diabetes mellitus have now been identified (1). 
The transcription factor GATA6 has been intensively studied after the discovery of its role in the development of the pancreas. 
In vertebrates GATA6 encodes a protein that belongs to the family of six GATA binding proteins. They bind to a 5'-(T/A)GATA(A/G)-3' consensus sequence in the promoters of target genes to regulate their transcription. 
GATA 4/5/6 are primary endodermal and mesodermal transcription factors. GATA4/6 are expressed in the primitive endoderm and extra-embryonic tissues that support the growing epiblast (2,3,4) and the proper endodermal differentiation (5).   During organogenesis GATA4/5/6 transcription factors support the anatomical and functional development of the pancreas, heart, blood vessels, hepatobiliary system, urogenital tract, thyroid gland as well as the brain (6). GATA 4/6 have a leading role in the transcriptional network hierarchy that works in pancreatic multipotent progenitors arising from the dorsal and ventral regions of the foregut endoderm (7,8,9). 
GATA4 is expressed in yolk sac endoderm and cells involved in heart formation (10). GATA4/5/6 are critical regulators of the other specific genes working in the endocardium, myocardium and great vessels (11,12,13). GATA4/6 persist in adult heart modulating cardiomyocyte differentiation, growth, hypertrophy and adaptive responses (14,15). 
In humans, GATA4 mutations were initially discovered to cause congenital cardiac septal  defects among family members (16) and  were found  in some individuals among screened series of 270, 310 and 21 patients with congenital non-syndromic cardiac septal or outflow defects (17,18,19). Further studies have shown that GATA4/6 haploinsufficiency can also cause a combination of pancreatic agenesis/hypoplasia, cardiac and hepatobiliary defects (20, 21, 22). 
The genetic finding in the family had previously been reported (De Franco et al, Diabetes), we now describe in detail the clinical features of the 2 patients and the marked phenotypic variability between affected family members.

Clinical case
Our patient, currently 10 years 8 months of age, was born to a healthy mother following a normal full term pregnancy. Intrauterine growth retardation was present with 41 cm length (-4.8 SDS) and 1600 g weight (-4.3 SDS). There were no apparent external malformations except for a small 1 cm hemangioma on the parietal skull area. 
After birth the first ultrasound cardiac investigation of the girl revealed foramen ovale, small patent ductus arteriosus (PDA) with persisting left-to-right shunting and peripheral stenosis of both branches of pulmonary artery. At the age of 9 days her condition worsened with dehydration, weight loss up to 1200 g, hyponatriemia and hyperglycemia of 30 mmol/l without ketonuria. Anti-GAD65, IAA and IA2 antibodies were all negative. On day 20, С-рeptide value was 73.1 pmol/l (normal range 174-960 pmol/l). Intensive insulin replacement therapy was started with diluted short-acting human insulin at a daily dose of 0.05 U/kg.
In the family, the father was born with normal birth weight. He underwent a cardiac operation in infancy for PDA and developed diabetes at the age of 12 years. He has always had mild insulin requirements and was treated with mixed insulin at a dose of 0.35U/kg b.w., two injections daily. He had no exocrine pancreatic insufficiency according to several clinical criteria: no gastrointestinal problems in early childhood, normal physical development with height of 178 cm, normal body mass index, normal abdominal circumference, normal stools. He has normal intellectual development and didn’t have any late diabetes complications at the age of 40 years. Further examinations in 2011 revealed glycated hemoglobin (HbA1c) 7.9% (4-6.2), normal hepatic function and lipid metabolism. His own insulin secretion measured by C-peptide was 88.2 pmol/l, being below normal ranges of 196-960 pmol/l. Ultrasound investigation revealed a hypoplastic thin pancreas with normal length and anatomical structure. Fecal elastase measured at his last visit was lower than 15 µg/g feces (normal >200 µg/g), suggesting subclinical pancreatic insufficiency.

Clinical course








Table 1. Laboratory signs of hepatic function

Age	ASAT*U/L	ALAT**U/L	GGT***U/L	Alkaline phosphataseU/L	Total bilirubin (µmol/L)(n<17)	Direct bilirubin (µmol/L)(n= 0-3.5)










Breast milk enriched in proteins and starch was given in the first few months after birth. Unusual large amount of carbohydrates, up to 20-22 g/kg b.w. (normal 12-14), was necessary for keeping weight gain. The corresponding insulin dose of 0.5U/kg b.w. was lower than usual for a patient with severe insulin defficiency. This could be explained with subclinical exocrine pancreatic insufficiency and maldigestion. Follow up C-peptide levels were recorded at 3 months (79.6 pmol/l) and 2 years (19.4 pmol/l). During the second year insulin dose reached 0.8-0.9 U/kg b.w. and weight gain was stable without significant fluctuations. Clinical signs of exocrine pancreatic insufficiency appeared after 2 years of age: abdominal distension, avoidance of bulky stools 5 to 7 times daily with steatorrhea with up to 50% of ingested fat. No weight loss was seen and insulin dose was stable 0.8-0.9 U/kg b.w. Unfortunately we could not investigate fecal elastase at the time. Ultrasound revealed initially a small pancreas with 3.5 mm length and replacement therapy with Creon and fat soluble vitamins A, E and D was initiated at age of 2 years 2 months. The enzyme dose used was similar to that of patients with cystic fibrosis -1000 Lipase units/kg b.w. per meal, Vitamin A 2000 U/d, Vitamin D 800 U/d, Vitamin E 50 U/d. At the age of 4 years MRI was performed and confirmed a diagnosis of pancreatic agenesis. Fecal elastase measured at her last visit was lower than 15 µg/g feces (normal >200 µg/g), suggesting pancreatic insufficiency.

Current status
The girl eats a normal traditional diet and receives three to four injections of short acting insulin analog before every meal and long acting insulin analog before bed, total daily dose of 20 U, 0.8 U/kg b.w. The dose of Creon is 75,000 to 100,000 U daily. At the last investigation plasma levels of fat-soluble vitamins under daily supplemental therapy were near the lower reference level: Vitamin A - 0.24 mg/L (0.3-0.8), Vitamin E (tocopherol) – 5.9 mg/L (5-18), 25-OH-Vitamin D -21.82 ng/mL (sufficiency level 30-100). 
At present (10 years 8 months of age) the girl’s height is 141cm (0.13 SDS), weight 27.6 kg (-0.97 SDS) (Fig.1). She has normal pubertal development with Tanner stage 3 and normal intellectual development with good school performance. She has normal physical activity and maintains good metabolic control with HbA1c 7 to 8%. Persisting small foramen ovale has been followed by cardiologists. 










Genetic testing and results.
Agenesis of pancreas had not been suspected up to 2 years of age because of detectable C-peptide and no clear clinical signs of exocrine pancreatic insufficiency. A first series of DNA analysis excluded mutations in the KCNJ11, ABCC8 and INS genes as well as biallelic mutations in GCK. After the diagnosis of pancreatic agenesis obtained by MRI, PDX1 and PTF1A gene mutations were excluded as well. 
Further analysis revealed a heterozygous GATA6 splicing mutation, c.1136-2A>G. This mutation affects the conserved splice acceptor site of intron 2 (c.1136-2A>G) and is predicted to cause aberrant splicing. Testing of parental samples revealed that it had been inherited from her father. This mutation is therefore very likely to be the cause of the girl's pancreatic agenesis and congenital heart defect as well as her father’s PDA and diabetes.The mutation was not found in the DNA sample from the paternal grandparents of the girl and is therefore likely to have arisen de novo in the father. 

Discussion 
We describe a family with autosomal dominant transmission of a GATA6 mutation causing a congenital heart defect (PDA) in two relatives, pancreas agenesis and PNDM in the daughter and pancreatic hypoplasia and juvenile-onset diabetes in the father. This case highlights the marked phenotypic variability, including a wide range of malformations and clinical problems that is seen in patients with mutations in GATA6. In a cohort of 171 neonatal diabetes patients with unknown cause 24 patients (3%) have been reported to have GATA6 mutations, 21 of them had complete absence or marked hypoplasia of the pancreas, including our patient. The most frequent extra-pancreatic features among patients with a GATA6 mutation were congenital heart defects (83%). One proband with PNDM and exocrine insufficiency (fecal elastase <15 µg/g) did not require treatment with pancreatic enzyme supplementation. Additional extra-pancreatic features include congenital hypothyroidism (n = 6), hepatobiliary malformations (n = 5), gut abnormalities (n = 6) and neurocognitive deficit (n=11). Some of the parents had late onset diabetes, but the others had isolated cardiac defects only (22).
GATA6 mutations have been identified in patients with PNDM with or without exocrine insufficiency, various cardiac deffects and idiopathic neonatal cholestasis (23,24). Our familial case of GATA6 haploinsufficiency presents the main clinical characteristics of the syndrome - diabetes and cardiac defect (21, 22, 23, 24, 25). In the familiar cases with GATA6 mutations it has been observed a variable penetrance of the diabetes phenotype, including the age of onset, severity of diabetes and exocrine insufficiency, whilst the cardiac phenotype is highly penetrant (22,26) In this family we observed variable clinical presentation of the pancreatic phenotype, with pancreatic agenesis (PNDM and exocrine insufficiency) in the proband but hypoplasia with juvenile onset diabetes and subclinical pancreatic insufficiency in the father. . The same low levels of C-peptide and fecal elastase measured in the daughter and in the father do not reflect real pancreatic endocrine and exocrine functional capacity in each of both patients. The mechanisms underlying this phenotypic variability are not well understood but they are likely to depend on genetic background and/or environmental influence. 
The proband is our first case with PNDM out of 4150 children with diabetes registered in the clinic since 1970, including 5 children with TNDM. 
It is useful to make a genetic diagnosis because it predicts other anomalies and clinical problems due to mutations in a particular gene and it allows assessment of recurrence risk which in this family is 50% in both the father and the daughter.

Conclusion 
Genetic analysis is important in cases of neonatal or later onset syndromic diabetes. Identification of the genetic defect guides treatment and allows prognosis and prenatal diagnosis. Identification of a GATA6 mutation in this family explains the cause of the syndromic neonatal and juvenile onset diabetes, although the mechanism underlying the phenotypic variability of the disease is not yet known. 
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